

Cover Story
Regulatory News
In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.
Cancer Policy


In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets
Trending Stories
- Gardiner Harris, acclaimed health care and pharma journalist, on his New York Times bestselling book
- Knight Cancer Institute receives record-setting $2B gift from the Knights—and self-governance within OHSU
Brian Druker returns to executive role as president of the new Knight Cancer Group - ACOG says it will no longer accept federal funding
- The Med Student’s Memo – Research Concerns
- Duke Officials Silenced Med Student Who Reported Trouble in Anil Potti’s Lab
- ANCHOR trial shows that treatment of anal high-grade squamous intraepithelial lesions prevents anal cancer in people with HIV